Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-03

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

NCT06024356

Colorectal Neoplasms

UNKNOWN

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

NCT06304987

Locally Advanced Rectal Cancer

NOT_YET_RECRUITING PHASE2

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

NCT06017583

Rectal Neoplasms

RECRUITING PHASE3

Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

NCT06493240

Locally Advanced Rectal Cancer

COMPLETED PHASE2

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

NCT05845268

Locally Advanced Rectal Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an open, prospective, multi-center, single-arm phase II clinical study. In this study, patients with pMMR/MSS locally advanced middle and low rectal cancer were selected as the subjects and treated with neoadjuvant treatment protocol of long-course concurrent chemoradiotherapy combined with PD-1 monoclonal antibody and thymalfasin. The primary endpoint of the study was complete response (CR) rate. The secondary end points included treatment-related adverse events (TRAEs) rate, 30-day incidence of postoperative complications, objective response rate (ORR), 3-year disease-free survival (DFS) rate, Neoadjuvant rectal cancer (NAR) score, R0 resection rate, and anal preservation rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

neoadjuvant chemoradiotherapy combined with PD-1 monoclonal antibody and thymalfasin

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cCRT+tislelizumab+thymalfasin

A total of 20 pMMR/MSS locally advanced middle and low rectal cancer patients will receive long-course concurrent chemoradiotherapy combined with 3 cycles of tislelizumab and 11 weeks of thymalfasin therapy.

Group Type EXPERIMENTAL

capecitabine

Intervention Type DRUG

825-1000mg/m2,po,bid

tislelizumab

Intervention Type DRUG

200mg,iv.gtt,q3w

thymalfasin

Intervention Type DRUG

4.8mg,sc,biw

long-term radiotherapy

Intervention Type RADIATION

50 Gy/25 f, 2 Gy/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

capecitabine

825-1000mg/m2,po,bid

Intervention Type DRUG

tislelizumab

200mg,iv.gtt,q3w

Intervention Type DRUG

thymalfasin

4.8mg,sc,biw

Intervention Type DRUG

long-term radiotherapy

50 Gy/25 f, 2 Gy/day

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who were fully informed of the study and voluntarily signed the informed consent form;
2. Patients with rectal cancers must satisfied all the following conditions:

1\) Stage II/III LARC (cT3-4aN0M0 and cT1-4aN1-2M0); 2) Tumor distal located ≤ 10 cm from anal verge (MRI diagnosed); 3) pMMR or MSS confirmed by immunohistochemistry or genetic test. 3.Patients regardless of gender with aged ≥18 years and ECOG score of 0 or 1; 4. Physical and viscera function of patients can withstand major abdominal surgery; 5.Patients are willing and able to follow the study protocol during the study 6.Patients give consent to the use of pathological specimens for study 7.Within 28 days prior to enrolment, we must confirm a negative serological pregnancy test for child-bearing age women and they agree to use effective contraception for the duration of drug use and for 60 days after the last dose.

Exclusion Criteria

1. Patients have a present or previous active malignancy except the diagnosis of rectal cancer this time;
2. Patients underwent major surgery within 4 weeks prior to study treatment;
3. Patients have any condition affects the absorption of capecitabine through gastrointestinal tract;
4. Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
5. Patients who are allergic to any of the ingredients under study;
6. Patients with severe concomitant diseases with estimated survival ≤ 5 years;
7. Patients with present or previous moderate or severe liver and kidney damage presently or previously;
8. Patients have received other study medications or any immunotherapy currently or in the past;
9. Patients preparing for or previously received organ or bone marrow transplant;
10. Patients who received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of study therapy;
11. Patients with congenital or acquired immune deficiency (such as HIV infection);
12. If patients with a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the investigator will determine whether the clinical severity prevents the signing of informed consent or affects the patient's oral medication compliance;
13. Patients with other factors that may affect the study results or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring combined treatment and severe laboratory examination abnormalities.
14. Pregnant or lactating women

Criteria for Withdrawal:

1. The subject withdraws informed consent;
2. The subject requests to withdraw from the study, or loses follow-up;
3. The subject demonstrates poor compliance and is unable to participate in the treatment and visits as required by the study protocol;
4. The subject experiences intolerable adverse events, and the investigator determines that continuing the study may be detrimental to the subject;
5. Other reasons, where the investigator determines it is not suitable for the subject to continue in the study.

Criteria for Study Termination:

1. There are major errors in the study protocol;
2. The study involves significant risks and is terminated following review by the ethics committee;
3. Termination requested by the sponsor or regulatory authorities.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No